{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:19:42Z","timestamp":1788394782039,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholinergic urticaria (CholU) is a common subtype of chronic inducible urticaria, where signs and symptoms (e.g. pruritic wheals and angioedema) are triggered by sweating due to physical exercise, passive warming and by other sweat-inducing situations. While guidelines recommend treatment with second-generation H1 antihistamines, approximately 90% of patients report uncontrolled disease. Targeting the histamine 4 receptor (H4R) has shown promise in preclinical\/clinical studies of allergic\/inflammatory diseases. Izuforant (LEO 152020) is a selective oral H4R antagonist with expected dual antipruritic and anti-inflammatory effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effects of izuforant in adults with CholU, a common type of chronic urticaria driven by histamine and characterized by high skin levels of H4R expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a phase IIa randomized double-blind placebo-controlled multicentre crossover trial where patients with CholU with an inadequate response to \u2265 1 standard dose of H1 antihistamine received izuforant 100\u2005mg twice daily or placebo (EUCTR2020-004961-38-DE; NCT04853992). The primary endpoint was change from baseline in Urticaria Activity Score. Exploratory endpoints included CholU activity score over 7\u2005days, urticaria control test, Physician Global Assessment, patient global assessment of severity (PGA-S), provocation tests, Dermatology Life Quality Index and CholU quality of life (CholU-QoL). Pharmacokinetic and pharmacodynamic parameters, and serum biomarkers were assessed, as well as safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen patients were randomized and included in the full analysis set; 18 completed treatment [mean (SD) age 29.5 (9.8) years; mean (SD) CholU duration 8.0 (6.3) years]. The primary and most of prespecified exploratory endpoints were not met; there were significant improvements in PGA-S for izuforant vs. placebo (P = 0.02), and nonsignificant improvements for other endpoints in quality of life and histamine skin prick test. All adverse events (AEs) experienced with izuforant were considered mild. The most frequently reported (&amp;gt; 1 patient) were nausea (three patients) and upper abdominal pain (two patients), occurring more frequently with izuforant vs. placebo (one patient each). There were no treatment-related serious AEs and no patient receiving izuforant discontinued the study. Treatment with izuforant did not cause downregulation of H4R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to explore the role of H4R as a therapeutic target in urticaria. Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements vs. placebo in the primary endpoint and all but one prespecified exploratory endpoint in CholU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae038","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T10:23:46Z","timestamp":1706955826000},"page":"825-835","source":"Crossref","is-referenced-by-count":12,"title":["Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial"],"prefix":"10.1093","volume":"190","author":[{"given":"Eva","family":"Grekowitz","sequence":"first","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Institute of Allergology , Berlin ,","place":["Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Institute of Allergology , Berlin ,","place":["Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Altrichter","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Institute of Allergology , Berlin ,","place":["Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology , Berlin ,","place":["Germany"]},{"name":"Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Biederstein, Technical University of Munich, Faculty of Medicine, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-9862","authenticated-orcid":false,"given":"Guido","family":"Heine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Lionnet","sequence":"additional","affiliation":[{"name":"GA2LEN Network of Urticaria Centers of Reference and Excellence (UCARE), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadriye Kaplan","family":"Saday","sequence":"additional","affiliation":[{"name":"LEO Pharma, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hultsch","sequence":"additional","affiliation":[{"name":"LEO Pharma, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole E","family":"S\u00f8erensen","sequence":"additional","affiliation":[{"name":"LEO Pharma, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Institute of Allergology , Berlin ,","place":["Germany"]},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"2026041404270157500_ljae038-B1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2229-5178.105493","article-title":"Prevalence of cholinergic urticaria in Indian adults","volume":"4","author":"Godse","year":"2013","journal-title":"Indian Dermatol Online J"},{"key":"2026041404270157500_ljae038-B2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0190-9622(94)70267-5","article-title":"Prevalence of cholinergic urticaria in young adults","volume":"31","author":"Zuberbier","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"2026041404270157500_ljae038-B3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"2026041404270157500_ljae038-B4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3904\/kjim.2017.203","article-title":"Epidemiology of urticaria including physical urticaria and angioedema in Korea","volume":"34","author":"Seo","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2026041404270157500_ljae038-B5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026041404270157500_ljae038-B6","doi-asserted-by":"crossref","first-page":"867227","DOI":"10.3389\/falgy.2022.867227","article-title":"Disease impact, diagnostic delay, and unmet medical needs of patients with cholinergic urticaria in German-speaking countries","volume":"3","author":"Altrichter","year":"2022","journal-title":"Front Allergy"},{"key":"2026041404270157500_ljae038-B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molimm.2014.05.007","article-title":"Functional characterization of histamine H4 receptor on human mast cells","volume":"62","author":"Jemima","year":"2014","journal-title":"Mol Immunol"},{"key":"2026041404270157500_ljae038-B8","doi-asserted-by":"crossref","first-page":"901851","DOI":"10.3389\/fimmu.2022.901851","article-title":"Evidence for histamine release in chronic inducible urticaria \u2013 a systematic review","volume":"13","author":"Kulthanan","year":"2022","journal-title":"Front Immunol"},{"key":"2026041404270157500_ljae038-B9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01873","article-title":"The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets","volume":"9","author":"Thangam","year":"2018","journal-title":"Front Immunol"},{"key":"2026041404270157500_ljae038-B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol Rev"},{"key":"2026041404270157500_ljae038-B11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40257-022-00728-6","article-title":"Cholinergic urticaria: subtype classification and clinical approach","volume":"24","author":"Fukunaga","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026041404270157500_ljae038-B12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10286-017-0418-6","article-title":"Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management","volume":"28","author":"Fukunaga","year":"2018","journal-title":"Clin Auton Res"},{"key":"2026041404270157500_ljae038-B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/187152306778772801","article-title":"Development and chemistry of histamine H4 receptor ligands as potential modulators of inflammatory and allergic responses","volume":"5","author":"Venable","year":"2006","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"2026041404270157500_ljae038-B14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2008.12.1110","article-title":"The histamine H4 receptor is functionally expressed on T(H)2 cells","volume":"123","author":"Gutzmer","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.13621","article-title":"Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u2018idiopathic\u2019) urticaria","volume":"172","author":"Kay","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026041404270157500_ljae038-B16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/cea.13023","article-title":"Cholinergic urticaria patients of different age groups have distinct features","volume":"47","author":"Asady","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2026041404270157500_ljae038-B17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/archderm.1987.01660280064024","article-title":"Cholinergic urticaria. a clinical and histologic study","volume":"123","author":"Hirschmann","year":"1987","journal-title":"Arch Dermatol"},{"key":"2026041404270157500_ljae038-B18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cellimm.2013.05.006","article-title":"Histamine receptor H4 regulates mast cell degranulation and IgE induced Fc\u03b5RI upregulation in murine bone marrow-derived mast cells","volume":"283","author":"Mirzahosseini","year":"2013","journal-title":"Cell Immunol"},{"key":"2026041404270157500_ljae038-B19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0923-1811(94)90088-4","article-title":"Demonstration of sweat allergy in cholinergic urticaria","volume":"7","author":"Adachi","year":"1994","journal-title":"J Dermatol Sci"},{"key":"2026041404270157500_ljae038-B20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2133.2008.08862.x","article-title":"Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis","volume":"160","author":"Takahagi","year":"2009","journal-title":"Br J Dermatol"},{"key":"2026041404270157500_ljae038-B21","author":"Wang"},{"key":"2026041404270157500_ljae038-B22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.imbio.2015.01.008","article-title":"Regulation of TNF-\u03b1 and NF-\u03baB activation through the JAK\/STAT signaling pathway downstream of histamine 4 receptor in a rat model of LPS-induced joint inflammation","volume":"220","author":"Ahmad","year":"2015","journal-title":"Immunobiology"},{"key":"2026041404270157500_ljae038-B23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.113.211714","article-title":"Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979","volume":"349","author":"Thurmond","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2026041404270157500_ljae038-B24","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/jdv.13765","article-title":"Atopic predisposition in cholinergic urticaria patients and its implications","volume":"30","author":"Altrichter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026041404270157500_ljae038-B25","doi-asserted-by":"crossref","first-page":"955161","DOI":"10.3389\/fimmu.2022.955161","article-title":"Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2026041404270157500_ljae038-B26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B27","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2023.03.034","article-title":"The 7-day recall period version of the Urticaria Control Test-UCT7","volume":"152","author":"Buttgereit","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B28","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jaci.2017.04.050","article-title":"Responsiveness and minimal important difference of the urticaria control test","volume":"140","author":"Ohanyan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdermsci.2014.04.007","article-title":"Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria","volume":"75","author":"Altrichter","year":"2014","journal-title":"J Dermatol Sci"},{"key":"2026041404270157500_ljae038-B31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF01652699","article-title":"Ein neues Verfahren zu den klinischen Untersuchungen der Schwei\u00dfabsonderung","volume":"101","author":"Minor","year":"101 1927","journal-title":"Dtsch Z Nervenheilkde"},{"issue":"3","key":"2026041404270157500_ljae038-B32","article-title":"The skin prick test \u2013 European standards","volume":"3","author":"Heinzerling","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"2026041404270157500_ljae038-B33","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bcp.14923","article-title":"Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a\/b randomised double-blind placebo-controlled study","volume":"87","author":"Dickson","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026041404270157500_ljae038-B34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cea.13102","article-title":"Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL)","volume":"48","author":"Ruft","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2026041404270157500_ljae038-B35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdermsci.2016.04.011","article-title":"Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo","volume":"83","author":"Ehling","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2026041404270157500_ljae038-B36","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2174\/0929867322666150311151905","article-title":"Human eosinophils \u2013 potential pharmacological model applied in human histamine H4 receptor research","volume":"22","author":"Grosicki","year":"2015","journal-title":"Curr Med Chem"},{"key":"2026041404270157500_ljae038-B37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/jcm4040741","article-title":"Histamine and skin barrier: are histamine antagonists useful for the prevention or treatment of atopic dermatitis?","volume":"4","author":"De Benedetto","year":"2015","journal-title":"J Clin Med"},{"key":"2026041404270157500_ljae038-B38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/cea.13154","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H(4) R-antagonist (JNJ-39758979) in adults with uncontrolled asthma","volume":"48","author":"Kollmeier","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2026041404270157500_ljae038-B39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.114.215749","article-title":"The histamine H\u2084 receptor antagonist, JNJ 39758979, is effective in reducing histamine-\u00adinduced pruritus in a randomized clinical study in healthy subjects","volume":"350","author":"Kollmeier","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2026041404270157500_ljae038-B40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"key":"2026041404270157500_ljae038-B41","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H(4) receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026041404270157500_ljae038-B43","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1398-9995.2012.02854.x","article-title":"The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-\u00adpruritic and anti-inflammatory effects in NC\/Nga mice","volume":"67","author":"Ohsawa","year":"2012","journal-title":"Allergy"},{"key":"2026041404270157500_ljae038-B44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jdermsci.2017.04.004","article-title":"Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis","volume":"87","author":"K\u00f6chling","year":"2017","journal-title":"J Dermatol Sci"},{"key":"2026041404270157500_ljae038-B45","doi-asserted-by":"crossref","first-page":"e87296","DOI":"10.1371\/journal.pone.0087296","article-title":"Delineating the role of histamine-1- and -4-receptors in a mouse model of Th2-dependent antigen-specific skin inflammation","volume":"9","author":"Mahapatra","year":"2014","journal-title":"PLOS ONE"},{"key":"2026041404270157500_ljae038-B46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026041404270157500_ljae038-B47","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/jid.2009.358","article-title":"The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation","volume":"130","author":"Cowden","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2026041404270157500_ljae038-B48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejphar.2011.05.037","article-title":"Histamine H(4) receptor antagonist reduces dermal inflammation and pruritus in a hapten-\u00adinduced experimental model","volume":"667","author":"Suwa","year":"2011","journal-title":"Eur J Pharmacol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae038\/57417285\/ljae038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/6\/825\/57724896\/ljae038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/6\/825\/57724896\/ljae038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:27:14Z","timestamp":1776155234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/6\/825\/7599651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,3]]},"published-print":{"date-parts":[[2024,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae038","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,2,3]]}}}